United States Food and Drug Administration (USFDA) has successfully completed its inspection at the manufacturing facility of Apnar Pharma, a subsidiary company of Senores Pharmaceuticals, situated at Vadodara. The inspection was conducted from September 07, 2026, till September 11, 2026 and concluded with one minor procedural and no GMP-related observation. The subsidiary company will submit its response within the stipulated timeframe.
Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms.
